FAQs

Duke is collaborating with Deerfield, an investment firm dedicated to advancing healthcare, to accelerate the translation of research in Duke faculty laboratories into clinical therapeutics. Four Points is a Deerfield company that will support Duke's innovative translational research and leverage Deerfield's expertise in accelerating state-of-the-art drug development. Four Points will fund projects with the aim of discovering novel therapeutics to cure life-altering diseases.

Through Four Points, Deerfield has committed up to $130 million in initial funding to support promising Duke translational research. This collaboration will provide operational support and may make additional capital investments into spin-off companies that emerge from Four Points projects that show commercial potential.

Principal Investigators whose principal employer is Duke University or Duke University Health System or who have a faculty appointment at Duke University and are therefore subject to Duke's institutional policies are eligible to apply.

Applicants are encouraged to contact Bryan Baines (bryan.baines@duke.edu) for more information on submission to Four Points.

No - We welcome applications from all therapeutic areas.